Last reviewed · How we verify
BRENTUXIMAB VEDOTIN
At a glance
| Generic name | BRENTUXIMAB VEDOTIN |
|---|---|
| Drug class | CD30-directed Immunoconjugate [EPC] |
| Modality | Antibody drug conjugate |
| Phase | FDA-approved |
| First approval | 2011 |
Approved indications
Boxed warnings
- WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS [see Warnings and Precautions (5.9) , Adverse Reactions (6.1) ] . WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) See full prescribing information for complete boxed warning. JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS ( 5.9 , 6.1 ).
Common side effects
- Peripheral neuropathy
- Nausea
- Fatigue
- Musculoskeletal pain
- Constipation
- Diarrhea
- Vomiting
- Pyrexia
- Upper respiratory tract infection
- Mucositis
- Abdominal pain
- Rash
Serious adverse events
- Neutropenia
- Anemia
- Thrombocytopenia
- Febrile neutropenia
- Stomatitis
- Infection
Key clinical trials
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment (PHASE2, PHASE3)
- Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (PHASE3)
- Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (PHASE2)
- BV-CHP Real-life and Biological Evidences in Patients With sALCL
- Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRENTUXIMAB VEDOTIN CI brief — competitive landscape report
- BRENTUXIMAB VEDOTIN updates RSS · CI watch RSS